Wire · operational-macro
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
Teva has received U.S. FDA approval for DEGEVMA™, a biosimilar to Xgeva® (denosumab), expanding its denosumab biosimilar portfolio in the U.S. This approval provides more affordable treatment options for bone complications related to cancer, giant cell tumors, and hypercalcemia of malignancy.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 28 Sep 2026 and 30 Sep 2026.
◆ ◆ The Wire takeaway
You can now offer lower-cost biosimilars for bone complications in cancer care as FDA approval opens the U.S. market to Teva's denosumab alternatives. This shift lets you challenge existing biologic suppliers and expand treatment access while cutting healthcare costs.
◆ Coverage
3 sources · first reported 28 Sep 2026 · latest 30 Sep 2026
◆ Related on Wire
◆ Topics